Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249108 | 0.90 | POLB (0.38) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL13820023 | 0.89 | POLB (0.32) | POLBLMNA | |
| SCHEMBL21325428 | 0.85 | SLC6A2 (0.36) | KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15417666 | 0.81 | LMNA (0.43) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL13310634 | 0.81 | AR (0.45) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL23985503 | 0.79 | SLC6A2 (0.34) | LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13270149 | 0.79 | LMNA (0.41) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL18872037 | 0.78 | AR (0.37) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL1780648 | 0.78 | LMNA (0.40) | POLBLMNAIDH1IDH2AR | |
| SCHEMBL29168008 | 0.78 | LMNA (0.37) | POLBLMNAIDH1IDH2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | claimed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | claimed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9095138-B2 | Isoxazoline insecticides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150098928-A9 | ISOXAZOLINE INSECTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | US | disclosed |
| US-20140127165-A1 | ISOXAZOLINE INSECTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-08 | — | — | US | disclosed |
| US-8623875-B2 | Isoxazoline insecticides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20100179195-A1 | ISOXAZOLINE INSECTICIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2010-07-15 | — | — | US | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1448554-A1 | PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003031437-A1 | PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | POLB 3674/4885LMNA 3009/4885IDH1 2419/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | POLB 4763/4885LMNA 649/4885IDH1 348/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | POLB 4763/4885LMNA 649/4885IDH1 348/4885 |
| US-20150098928-A9 | ISOXAZOLINE INSECTICIDES | CBR3, CYP4X1, PRDX1 | POLB 4204/4885LMNA 3243/4885IDH1 558/4885 |
| US-20140127165-A1 | ISOXAZOLINE INSECTICIDES | CBR3, CYP4X1, PRDX1 | POLB 4204/4885LMNA 3243/4885IDH1 558/4885 |
| US-20100179195-A1 | ISOXAZOLINE INSECTICIDES | CBR3, CYP4X1, PRDX1 | POLB 4204/4885LMNA 3243/4885IDH1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.